³ΙΘΛΏμΚΦ

header-logo
GettyImages-609179959-hero
headshot

Ehab L. Atallah, MD

Professor

view provider profile

Locations

  • Froedtert Hospital
  • Clinical Cancer Center - Froedtert Hospital
  • Zablocki VA Medical Center
  • Cancer Center - Moorland Reserve Health Center

Specialties

  • Medical Oncology
  • Hematology

Languages

  • Arabic, English

Clinical Cancer Center - Froedtert Hospital

Moorland Reserve Health Center

Education

  • MD - Doctor of Medicine

Publications

  • (Uczkowski D, Hobbs LM, Yohay S, Ettyreddy A, Uczkowski NG, Lin C, Coltoff A, Michaelis LC, Kreuziger LB, Shah NN, Atallah E.) Leuk Res. 2026 Nov;170:108321 PMID: 42762796 SCOPUS ID: 2-s2.0-105051083409 09/19/2026

  • (Guru Murthy GS, Shah B, Badar T, Leonard J, DuVall A, Arana Yi C, Szabo A, Baim A, Harrington A, Runaas L, Carlson K, Michaelis L, Abedin S, Kearl T, Atallah E.) Leukemia. 2026 Sep 14 PMID: 42736326 SCOPUS ID: 2-s2.0-105050660806 09/15/2026

  • (Badar T, Foran J, Jamy O, Lin C, Patel A, Wang YH, Kumar M, Shallis RM, Diebold K, Coltoff A, Goldberg AD, Bewersdorf JP, Zabel KM, Foucar C, Abaza Y, Murthy GS, Palmisiano N, DuVall AS, Kota V, Patel SA, Zeidan AM, Murthy H, Kharfan-Dabaja M, Atallah E, Litzow MR.) Leukemia. 2026 Aug 31 PMID: 42675141 SCOPUS ID: 2-s2.0-105048881032 09/01/2026

  • (Fradin JJ, Rein L, Szabo A, Carlson KS, Badar T, Holden T, Shah S, Im A, Patel AA, Atallah E.) Leuk Lymphoma. 2026 Aug;67(10):2064-2072 PMID: 42281276 SCOPUS ID: 2-s2.0-105041841666 06/12/2026

  • (Flynn KE, Atallah E.) Haematologica. 2026 Jul 01;111(7):2281-2290 PMID: 41376566 PMCID: PMC13317834 SCOPUS ID: 2-s2.0-105044670985 12/11/2025

  • (Mohty R, Narra R, Mims AS, Hunter C, Shallis RM, Kota V, Jamy O, Coltoff A, Othman TA, Jonas BA, Patel AA, DuVall AS, Foucar CE, Abdelsamia M, Palmisiano N, Patel SA, Curran E, Omer Z, Advani A, Atallah E, Litzow MR, Badar T.) Leuk Lymphoma. 2026 Jun;67(7):1587-1594 PMID: 41954351 SCOPUS ID: 2-s2.0-105035162707 04/09/2026

  • (Yates SJ, Weiss JJ, Sneider A, Geramita E, Murthy GSG, Badar T, Im A, Lin C, Cheng W, Abaza Y, Swaroop A, Winer ES, Litzow MR, Atallah EL, Patel AA, Shallis RM.) Haematologica. 2026 Jan 01;111(1):158-167 PMID: 40702896 PMCID: PMC12775749 SCOPUS ID: 2-s2.0-105026884925 07/24/2025

  • (Atallah E, Broder MS, Chan O, Flynn KE, Gilreath JA, Hine M, Hunter AM, Mattson HTD, Mauro MJ, Pinilla-Ibarz J, Rein LAM, Stemper E, Tantravahi S, Yang J, Shah NP.) Hematology. 2025 Dec;30(1):2556506 PMID: 41054963 SCOPUS ID: 2-s2.0-105017950500 10/07/2025

  • (Jamy O, El Kettani M, Shah K, Shallis RM, Diebold K, Coltoff A, Goldberg AD, Patel A, Bewersdorf JP, Foucar C, Abaza Y, Palmisiano N, DuVall AS, Kota V, Patel SA, Zeidan AM, Atallah E, Litzow MR, Badar T.) Blood Cancer J. 2025 Oct 07;15(1):160 PMID: 41057316 PMCID: PMC12504439 SCOPUS ID: 2-s2.0-105018128634 10/08/2025

  • (Atallah EL, Sadek I, Wei D, Latremouille-Viau D, Rossi C, Damon A, Yang D, Bellefleur R, Guérin A, Jadhav K.) Leuk Res. 2025 Oct;157:108089 PMID: 40940227 SCOPUS ID: 2-s2.0-105015980212 09/13/2025

  • (Badar T, Foran JM, Bewersdorf JP, Wang YH, Coltoff A, El Kettani M, Shah K, Denis Oliva F, Lin C, Jamy O, Diebold K, Shallis RM, Siddon A, Katkov D, Schoen A, Khan I, Foucar CE, Atallah E, Goldberg AD, Patel AA.) Br J Haematol. 2025 Aug;207(2):683-686 PMID: 40400334 SCOPUS ID: 2-s2.0-105005993894 05/22/2025

  • (Atallah E, Lipton JH.) Cancer. 2025 May 15;131(10):e35880 PMID: 40366989 SCOPUS ID: 2-s2.0-105005107180 05/14/2025

Publications of from the

© 2026 ³ΙΘΛΏμΚΦ.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The ³ΙΘΛΏμΚΦ (³ΙΘΛΏμΚΦ) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. ³ΙΘΛΏμΚΦ maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

³ΙΘΛΏμΚΦ's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the ³ΙΘΛΏμΚΦ community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.